Pharmena S.A.

Warsaw Stock Exchange PHR.WA

Pharmena S.A. Price to Sales Ratio (P/S) on January 14, 2025: 4.50

Pharmena S.A. Price to Sales Ratio (P/S) is 4.50 on January 14, 2025, a -47.69% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Pharmena S.A. 52-week high Price to Sales Ratio (P/S) is 10.09 on April 04, 2024, which is 124.05% above the current Price to Sales Ratio (P/S).
  • Pharmena S.A. 52-week low Price to Sales Ratio (P/S) is 4.00 on December 23, 2024, which is -11.13% below the current Price to Sales Ratio (P/S).
  • Pharmena S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 6.91.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Warsaw Stock Exchange: PHR.WA

Pharmena S.A.

CEO Mr. Konrad Palka
IPO Date Aug. 1, 2008
Location Poland
Headquarters ul. Wólczanska 178
Employees 15
Sector Health Care
Industries
Pharmaceuticals Biotechnology Cosmetics
Description

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.

StockViz Staff

January 15, 2025

Any question? Send us an email